NCT02226939 Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C Status COMPLETED Phase PHASE2
NCT02226926 Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers Status COMPLETED Phase PHASE1
NCT02225626 Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects Status COMPLETED Phase PHASE1
NCT02224105 Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects Status COMPLETED Phase PHASE1
NCT02224079 Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT02223507 Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers Status COMPLETED Phase PHASE1
NCT02223494 Safety of Terbogrel in Patients With Primary Pulmonary Hypertension Status TERMINATED Phase PHASE2
NCT02223481 Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension Status COMPLETED Phase PHASE2
NCT02223260 Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Status COMPLETED Phase PHASE2
NCT02223026 Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects Status COMPLETED Phase PHASE1
NCT02223013 Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects Status COMPLETED Phase PHASE1
NCT02223000 Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects Status COMPLETED Phase PHASE1
NCT02222987 Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects Status COMPLETED Phase PHASE1
NCT02222974 Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL Status COMPLETED Phase PHASE1
NCT02222961 Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT02222428 Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers Status COMPLETED Phase PHASE1
NCT02222233 Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT02222168 Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT02221414 Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers Status COMPLETED Phase PHASE1